Seoul Yes Bio Co., Ltd., a company engaged in the development of advanced regenerative medicine technologies and therapeutic services, announced that it has signed a three-party Memorandum of Understanding (MOU) with Seoul Yes Hospital and XEME Biopharma, a U.S.-based developer of cancer immunotherapies, to collaborate on joint research and development and business cooperation for advanced regenerative medicine clinical research and treatment.

XEME Biopharma has developed personalized cancer vaccine cell therapies using its proprietary platform technology, “Aggregon,” and is currently conducting clinical trials in the U.S., where the treatments are reportedly showing excellent therapeutic effects.

In particular, XEME Biopharma noted the revision of South Korea’s Advanced Regenerative Medicine Act last February, concluding that this has created conditions enabling faster delivery of treatments to patients in Korea. Consequently, the company announced that it has signed an MOU with Seo-Seoul Yes Bio and Seoul Yes Hospital, which play leading roles in the advanced regenerative medicine sector in South Korea.

The three institutions that signed this agreement plan to fully engage in advanced regenerative medicine clinical research, aiming to develop new cancer treatments by leveraging their respective core technologies and capabilities. Seoul Yes Bio and Seoul Yes Hospital will conduct clinical research and treatment for cancer-related diseases, such as blood cancers, while JimBioPharma will supply the cancer vaccine therapies.

Additionally, the companies plan to jointly pursue global expansion by collaborating with Seoul Yes Hospital’s partner hospitals located in Japan, Indonesia, and other countries where regenerative medicine treatments can be rapidly implemented, in addition to Korea.

Seoul Yes Hospital was designated as an Advanced Regenerative Medicine Implementation Institution by the Ministry of Health and Welfare in December 2024 and secured a license for a cell processing facility from the Ministry of Food and Drug Safety, thereby laying the groundwork for its entry into advanced regenerative medicine. Through this agreement, the hospital has expanded its clinical research pipeline to include the field of cancer treatment.

Seoul Yes Bio is a biotech company dedicated to the development and commercialization of cell therapies through advanced regenerative medicine research. Currently, under the leadership of Dr. Cho Seong-hoon, a leading authority in the field of regenerative medicine, the company is continuing its R&D efforts and is jointly developing bone marrow-derived stem cell therapies and immune cell therapies with Seoul Yes Hospital.

Dr. Lee Gil-yong, Chief Executive Officer of Seoul Yes Hospital, stated, “GimBioPharma’s personalized cancer vaccine therapy is a technology that has already undergone clinical trials in the U.S. and proven its safety and efficacy, and we expect it to offer hope to cancer patients as a new treatment option.” He added, “We will expand beyond our ongoing clinical research on musculoskeletal disorders and focus our capabilities on successfully conducting clinical research to lead the market in the field of cancer treatment as well.”